Presented at ASCO GU by Stolten and colleagues was abstract 244 that described the responses African American men had to abiraterone (Zytiga) in a retrospective cohort study of men seen at a single institution. Stolten included differences in the men including their age at diagnosis, prior enzalutamide (Xtandi) and/or docetaxel (chemotherapy) use, as well as baseline alkaline phosphatase, hemoglobin, and lactate dehydrogenase. The primary outcome of interest was duration of treatment with Zytiga and they considered velocity of PSA decline, PSA response and progression as a secondary outcomes.
The treatment sample included 103 men with metastatic castration-resistant prostate cancer (mCRPC) who were treated with abiraterone during the period of the study. The sample size included 24 African American men and 79 Caucasian men.